DR6 Stock Chart & Stats
€24.73
€0.25(1.15%)
At close: 4:00 PM EDT
€24.73
€0.25(1.15%)
Day’s Range― - ―
52-Week Range€17.52 - €25.98
Previous CloseN/A
Volume0.00
Average Volume (3M)13.00
Market Cap
€4.00B
Enterprise Value€3.49K
Total Cash (Recent Filing)€956.47M
Total Debt (Recent Filing)€73.85M
Price to Earnings (P/E)11.3
Beta0.47
Next Earnings
Nov 11, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.25
Shares Outstanding172,305,510
10 Day Avg. Volume0
30 Day Avg. Volume13
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.69
Price to Sales (P/S)4.22
P/FCF Ratio43.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.32Price Target Upside18.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)0.54
Revenue Forecast (FY)€1.12B
Bulls Say, Bears Say
Bulls Say
Commercial GrowthBoth marketed products are contributing to growth, reducing reliance on a single commercial asset. DAYBUE is scaling rapidly while NUPLAZID continues to expand through higher volume and prescriptions, supporting durable revenue growth over the next several quarters.
Profitability And Balance SheetACADIA has moved from historical losses to substantial profitability while maintaining very modest leverage. The combination of strong earnings, low debt, and expanding equity provides financial flexibility to fund commercialization, research, and potential business development.
Pipeline And Regulatory ExpansionRegulatory progress for trofinetide can broaden DAYBUE’s geographic opportunity, while the advancing remlifanserin program adds a potential future CNS growth driver. These developments strengthen the company’s product portfolio beyond its current U.S. sales base.
Bears Say
Remlifanserin Efficacy UncertaintyThe primary-endpoint miss increases uncertainty around remlifanserin’s probability of success despite positive secondary-endpoint and safety observations. Continued Phase III development may preserve upside, but equivocal efficacy evidence could delay or reduce the pipeline’s contribution.
Uneven Cash GenerationACADIA is generating positive cash, but the recent free-cash-flow decline and mixed conversion from reported profits indicate that earnings are not translating consistently into cash. Persistent variability could limit internally funded investment and make operating discipline more important.
Gross-to-net Pressure And CostsLarge deductions from gross sales reduce realized revenue and can pressure margins even while prescriptions grow. At the same time, higher commercial spending raises the cost of maintaining momentum, creating execution risk if sales expansion does not outpace access deductions and operating expense growth.
ACADIA Pharmaceuticals News
DR6 FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was €17.52 and its highest was €25.98 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is €4.00B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 46 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Aug 04, 2026. The company reported €0.158 earnings per share for the quarter, beating the consensus estimate of €0.06 by €0.098.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.17.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 172,305,510 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of €0.158 in its last earnings report, beating expectations of €0.06. Following the earnings report the stock price went up 5.959%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:DR6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€29.32 (18.58% Upside)
€29.32 (18.58% Upside)
Blogger Sentiment
Bullish
DE:DR6 Sentiment 75%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 45%
Bearish news 55%
Bearish news 55%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
42.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
DR6 Company Deck
DR6 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear near-term catalysts: robust Q2 results (total revenues +17%), pronounced DAYBUE STIX uptake (DAYBUE +30% YoY), healthy NUPLAZID growth (+10% YoY) with new prescriptions up 20%, a positive CHMP opinion for trofinetide in Europe, and significant pipeline progress (remlifanserin Phase II enrollment complete, Fast Track designation, top-line data expected Sep–Oct 2026). Offsetting factors include rising SG&A, sizable gross‑to‑net adjustments (~24%), a lowered R&D spend guidance due to a shifted BD milestone, reimbursement and pricing uncertainties in Europe, and dependency on upcoming pivotal readouts (creating execution/timing risk). Overall, the positives — strong sales, upgraded DAYBUE guidance, regulatory wins and a deepening pipeline with imminent binary catalysts — outweigh the operational and timing risks presented.View all DE:DR6 earnings summariesDR6 Stock 12 Month Forecast
Average Price Target
€29.32
▲(18.58% Upside)
Technical Analysis
PTC Therapeutics
―
Xenon
―
Harmony Biosciences Holdings
―
Immix Biopharma
―
Biohaven Ltd.
―